Riccardo Soffietti

CTO Hospital — Italy

Medicine · Health Sciences

72h-index38.8kcitations613works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(394), Brain Metastases and Treatment(274), Meningioma and schwannoma management(77), Lung Cancer Research Studies(53), Radiomics and Machine Learning in Medical Imaging(49)

Publications600 total

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Journal of Clinical Oncology·2025Open Access
Neuro-oncology is moving quickly toward new horizons of diagnosis and treatment
Current Opinion in Neurology·2025
Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies
Blood·2025
IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
Neuro-Oncology·2025Open Access
IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
Neuro-Oncology·2025Open Access
INNV-25. Efficacy of dabrafenib plus trametinib in <i>BRAF</i> -mutant gliomas: a retrospective series
Neuro-Oncology·2025Open Access
TMIC-07. pSTAT3 expression in patients with brain metastases from breast cancer: association with molecular subtypes and impact on overall survival
Neuro-Oncology·2025Open Access
CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA
Neuro-Oncology·2025Open Access
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology·2025· 6 cited
JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB
Neuro-Oncology·2025Open Access
P11.06.A PATTERNS OF PSTAT3 EXPRESSION IN REACTIVE ASTROCYTES OF BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER AND CORRELATIONS WITH OUTCOME
Neuro-Oncology·2025Open Access
P17.44.B DOES GRADING IN OLIGODENDROGLIOMAS STILL MATTER? RESULTS FROM AN OBSERVATIONAL, LONG-TERM CLINICO-THERAPEUTIC COHORT.
Neuro-Oncology·2025Open Access
OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
Neuro-Oncology·2025Open Access
P16.02.B DISPARITIES IN TRIAL ACCESS FOR GLIOMA PATIENTS: COMPARISON ACROSS SELECTED EUROPEAN COUNTRIES
Neuro-Oncology·2025Open Access
Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative
Neuro-Oncology·2025· 1 citedOpen Access
STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome
Neuro-Oncology·2025Open Access
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
The Lancet Oncology·2025· 13 citedOpen Access
RANO seizure working group-Tumor-Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice
Neuro-Oncology·2025· 4 citedOpen Access
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Neuro-Oncology·2025· 1 citedOpen Access
Low-grade <i>IDH</i> -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors
Expert Opinion on Pharmacotherapy·2025
page 1 of 30Next →

Frequent Co-authors

Roberta Rudà(19), Michael Weller(17), Martin J. van den Bent(10), Matthias Preusser(10), Émilie Le Rhun(10), Patrick Y. Wen(10), Brigitta G. Baumert(7), Nancy U. Lin(7), Michael A. Vogelbaum(7), Wolfgang Wick(6), Eudocia Q. Lee(6), Guido Reifenberger(5), Jörg C. Tonn(5), Roger Stupp(5), Roger Henriksson(5), Alba A. Brandes(5), Minesh P. Mehta(5), Manmeet S. Ahluwalia(5), Andreas von Deimling(4), Ufuk Abacıoğlu(4)